SLRX — Salarius Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
Salarius Pharmaceuticals Inc (SLRX) is a biotechnology company listed on NASDAQ. It is led by Frederick E. Pierce II, based in 2450 Holcombe Blvd., Houston, TX, United States, 77021, with about 2 employees. Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. Salarius Pharmaceuticals, Inc. is based in Houston, Texas.
Net income was -$873.5K. SLRX currently screens at market cap $4.9M.
Use this SLRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SLRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SLRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Salarius Pharmaceuticals Inc even when a live quote feed is slow.
About Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. Salarius Pharmaceuticals, Inc. is based in Houston, Texas.
SLRX Key Statistics
Market Cap
$4.92M
P/B Ratio
1.13
EPS
-$5.79
Revenue
$0.00
Net Income
-$5.58M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
2
SLRX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $1.84M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$5.58M | -$12.54M | -$31.61M | -$12.77M |
| EPS (Diluted) | -$5.79 | -$30.74 | -$14.88 | -$7.72 |
Total Assets
$3.02M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$2.43M
Operating Cash Flow
-$4.53M
Free Cash Flow
$0.00
Salarius Pharmaceuticals Inc Company Information
- CEO & Director
- Frederick E. Pierce II
- Headquarters
- 2450 Holcombe Blvd., Houston, TX, United States, 77021
- Website
- www.salariuspharma.com
- Phone
- 713 913 5608
- IPO / Founded
- 2015-01-29
- Sector
- Healthcare
- Industry
- Biotechnology